Providence to Expand Access to In-home, Outpatient PT with Luna

Luna, the leading provider of in-home physical therapy, today announced that Providence, a not-for-profit health system serving the Western U.S., will expand access to outpatient physical therapy service through the Luna technology platform.

The Luna technology platform will match eligible Providence patients to therapists based on factors, including specialty, geography, and schedules. Luna’s broad network of local physical therapists will provide consistent, high-quality care, of the type administered in a traditional outpatient clinic, but from the comfort of a patient’s home.

“Providence is an innovative health system that is continuously finding ways to meet patients where they are,” said Prasanna Mohanty, chief operating officer for the clinical network at Providence. “We recognize that there is a growing number of physical therapy outpatients needing or wanting to remain at home, and Luna’s in-home model will enable our teams to accommodate patient needs and ensure quality care that is safe and convenient.”

The platform will allow patients and therapists to communicate with each other and discuss care needs between visits. The same therapist will treat the patient for the entirety of the treatment plan, which will ensure consistent and quality care. Between visits, patients will use the Luna platform to communicate with their physical therapists, set appointment times, and perform therapist-prescribed and monitored exercises.

Providence

“Patients demand greater flexibility in outpatient services, including the ability to choose when and where services are performed,” said Palak Shah, co-founder and head of clinical operations at Luna. “The addition of Luna’s in-home physical therapy provides relief for health systems operating at capacity and needing more access. This will allow more patients within the Providence health system to complete their treatment plan at a convenient place and time — and ensure quality and continuity of care.”

Luna will accept all insurance providers contracted with Providence, with the exception of worker’s compensation and disability.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version